SpliceBio key facts
as of Oct 2026- Operator of a biotechnology company intended to develop genetic medicines through protein-splicing gene therapy.
- SpliceBio is valued at approximately $84.5M as of Oct 2026 (last reported valuation).
- It has raised $198.0M; the latest was Later Stage VC ($134.7M) in Jun 2025.
- Notable investors include New Enterprise Associates, EQT Life Sciences, Gilde Healthcare, Novartis Venture Fund, Caixa Capital Risc — 11 tracked in total.
- Status: Privately Held (backing).
SpliceBio's last reported valuation, Feb 2022. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch SpliceBio: the Monday email on marks, rounds and moves
SpliceBio funding rounds
No funding rounds for SpliceBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs SpliceBio
11+SpliceBio valuation
SpliceBio's last reported valuation was $84.5 million in Feb 2022. No priced round, secondary trade or fund mark has surfaced since.
SpliceBio investors
11 investors are on record for SpliceBio, including New Enterprise Associates, EQT Life Sciences, Gilde Healthcare and Novartis Venture Fund.
About SpliceBio
Operator of a biotechnology company intended to develop genetic medicines through protein-splicing gene therapy. The company's platform allows addressing of adeno-associated viruses, both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted and further used to treat patients that suffer from incurable genetic diseases, enabling clients to develop and produce biotherapeutics that overcome the limitations of natural inteins.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2012
- Employees
- 45
- Website
- splice.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.